Stifel on Apogee Therapeutics Inc (APGE): 'data further derisks Zumilokibart's TPP,' approval path
Tweet Send to a Friend
Stifel analyst Alex Thompson reiterated a Buy rating and $133.00 price target on Apogee Therapeutics Inc (NASDAQ: APGE)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
